Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.13
-0.3400-1.51%
Post-market: 22.00-0.1300-0.59%16:15 EST
Volume:3.87M
Turnover:84.96M
Market Cap:2.80B
PE:61.79
High:22.67
Open:21.12
Low:20.10
Close:22.47
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:2.20
T/O Rate:4.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:6.98
PE(LYR):-13.86

Loading ...

Apellis posts FY2025 U.S. net product revenues of USD 689 million with SYFOVRE generating USD 587 million

Reuters
·
Jan 12

Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE?

Simply Wall St.
·
Jan 09

S&P 500 Hits New Record Highs, Alphabet Dethrones Apple: What's Moving Markets Wednesday?

Benzinga
·
Jan 08

Apellis Pharmaceuticals Inc : Stifel Cuts Target Price to $48 From $55

THOMSON REUTERS
·
Dec 19, 2025

U.S. RESEARCH ROUNDUP-Carmax, Cintas, Nike

Reuters
·
Dec 19, 2025

Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Is Apellis Pharmaceuticals Attractive After Recent 26% Surge Despite Mixed Valuation Signals?

Simply Wall St.
·
Dec 13, 2025

Sobi Wins Positive CHMP Opinion for Aspaveli in Rare Kidney Diseases

Reuters
·
Dec 12, 2025

Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli

MT Newswires Live
·
Dec 04, 2025

Apellis Wins FDA Approval for EMPAVELI in Rare Kidney Diseases

Reuters
·
Dec 04, 2025

Assessing Apellis Pharmaceuticals (APLS) Valuation Following Five-Year SYFOVRE Efficacy Data in Geographic Atrophy

Simply Wall St.
·
Dec 03, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Reuters
·
Nov 25, 2025

Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares

Reuters
·
Nov 18, 2025

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 15, 2025

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Benzinga_recent_news
·
Nov 13, 2025

Apellis Pharmaceuticals: Safety Profile of Syfovre Through Five Years Remained Consistent With Previously Reported Data

THOMSON REUTERS
·
Nov 12, 2025

Apellis Announces 5-Year Gale Data Showing Syfovre® (Pegcetacoplan Injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

THOMSON REUTERS
·
Nov 12, 2025

Apellis Reports SYFOVRE Delays Geographic Atrophy Progression by 1.5 Years in Five-Year Study

Reuters
·
Nov 12, 2025

Apellis Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 06, 2025

Wolfe Research Initiates Coverage on Apellis Pharmaceuticals With Peer Perform Rating

MT Newswires Live
·
Nov 06, 2025